Agenus Extends Cash Runway In GSK Partnership Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.